Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.

Literature DB >> 27826875

Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.

Charles Faisant^1,2, Aurélie Du Thanh³, Catherine Mansard^4,5, Alban Deroux^4,5,6, Isabelle Boccon-Gibod^4,6, Laurence Bouillet^4,5,6,7.

Abstract

Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease characterized by AE resistant to antihistamines and a chronic course. We report five new cases of InH-AAE (two women and three men) with a rapid and dramatic response to the anti-immunoglobulin-E antibody omalizumab. In our literature review, we found 13 other relevant cases with a good response to this treatment. Overall, in 6 out of 18 patients, the doses of omalizumab required to prevent recurrences of attacks were higher than the licensed dose for chronic urticaria. No significant adverse effects have been reported.

Entities: Chemical Disease Species

Keywords: Idiopathic angioedema; non-histaminergic angioedema; omalizumab

Mesh：

Substances：

Year: 2016 PMID： 27826875 DOI： 10.1007/s10875-016-0345-7

Source DB: PubMed Journal: J Clin Immunol ISSN： 0271-9142 Impact factor: 8.317

25 in total

Review 1. Chronic urticaria.

Authors: M Greaves
Journal: J Allergy Clin Immunol Date: 2000-04 Impact factor: 10.793

2. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Authors: Marcus Maurer; Karin Rosén; Hsin-Ju Hsieh; Sarbjit Saini; Clive Grattan; Ana Gimenéz-Arnau; Sunil Agarwal; Ramona Doyle; Janice Canvin; Allen Kaplan; Thomas Casale
Journal: N Engl J Med Date: 2013-02-24 Impact factor: 91.245

3. Nonhistaminergic idiopathic angioedema: clinical response to icatibant.

Authors: C Colás; R Montoiro; J Fraj; M Garcés; J L Cubero; T Caballero
Journal: J Investig Allergol Clin Immunol Date: 2012 Impact factor: 4.333

4. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.

Authors: Sarbjit Saini; Karin E Rosen; Hsin-Ju Hsieh; Dennis A Wong; Edward Conner; Allen Kaplan; Sheldon Spector; Marcus Maurer
Journal: J Allergy Clin Immunol Date: 2011-07-18 Impact factor: 10.793

5. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study.

Authors: Riccardo Asero; Alberto Tedeschi; Massimo Cugno
Journal: Int Arch Allergy Immunol Date: 2010-03-04 Impact factor: 2.749

6. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

Authors: Allen Kaplan; Dennis Ledford; Mark Ashby; Janice Canvin; James L Zazzali; Edward Conner; Joachim Veith; Nikhil Kamath; Petra Staubach; Thilo Jakob; Robert G Stirling; Piotr Kuna; William Berger; Marcus Maurer; Karin Rosén
Journal: J Allergy Clin Immunol Date: 2013-07 Impact factor: 10.793

7. Successful treatment of refractory idiopathic angio-oedema with omalizumab: review of the literature and function of IgE in angio-oedema.

Authors: J Pedraz Muñoz; A Fueyo Casado; A Conde Taboada; L Campos Muñoz; E López Bran
Journal: Clin Exp Dermatol Date: 2015-12-09 Impact factor: 3.470

Review 8. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.

Authors: Tse Wen Chang; Christina Chen; Chien-Jen Lin; Martin Metz; Martin K Church; Marcus Maurer
Journal: J Allergy Clin Immunol Date: 2014-06-17 Impact factor: 10.793

9. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients.

Authors: C Wintenberger; I Boccon-Gibod; D Launay; O Fain; G Kanny; P Y Jeandel; L Martin; A Gompel; L Bouillet
Journal: Clin Exp Immunol Date: 2014-10 Impact factor: 4.330